P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Intravenous Pembrolizumab Combined with Intravesical Bacillus Calmette–Guérin (BCG) for Patients with BCG-Naïve “Very High-Risk” T1 Non-Muscle Invasive Bladder Cancer Traditionally Reco

P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Intravenous Pembrolizumab Combined with Intravesical Bacillus Calmette–Guérin (BCG) for Patients with BCG-Naïve “Very High-Risk” T1 Non-Muscle Invasive Bladder Cancer Traditionally Reco

Friday, May 15, 2026 10:50 AM to 11:00 AM · 10 min. (America/New_York)
Hall D
Detail

Registered attendees

Alexandre Danilovic
Alexandre Danilovic
Attending UrologistHospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Eila Skinner
Eila Skinner
Professor, Department of Urology, Stanford UniversityStanford University Department of Urology
Eugene Pietzak
Eugene Pietzak
Urologic OncologistMemorial Sloan Kettering Cancer Center

Log in

See all the content and easy-to-use features by logging in or registering!